Comparison of gene expression profiles reveals aberrant expression of FOXO1, Aurora A/B and EZH2 in lesional psoriatic skins.
Psoriasis is a chronic, non-infectious skin disease affects 2-3% of the population worldwide. In order to find genes possibly cause this skin disease, we re-analyzed the gene expression data-sets from three published studies. We compared the gene expression profiles between lesional psoriatic skin (PP), uninvolved psoriatic skin (PN) and normal skin (NN) tissues. We found that compared with in PN and NN tissues, the expression of FOXO1 is significantly repressed and the expression of AURKA, AURKB and EZH2 is significantly up-regulated in PP tissues (P < 0.001). During the treatment of psoriasis patients with TNF-α antagonist Etanercept, the expression of FOXO1 was re-activated and the expression of AURKA and EZH2 was repressed. These results suggest loss of FOXO1 expression and elevated AURKA/B and EZH2 expression in lesional psoriatic tissues have potential contribution to the development of psoriasis. It is worthwhile to test whether the combination of Aurora kinases or EZH2 inhibitors can enhance the therapeutic effects of Etanercept in psoriasis management.
Department of Dermatology, Zhuzhou No. 1 Hospital, Zhuzhou City, 412000, Hunan Province, PR China.
Yayan
Y
Liu
Wenhui
W
Luo
Shuai
S
Chen
D064096:Aurora Kinase A; D064107:Aurora Kinase B; D064127:Aurora Kinases; D004268:DNA-Binding Proteins / Q000235:genetics* / Q000378:metabolism; D000071221:Enhancer of Zeste Homolog 2 Protein; D000068800:Etanercept; D000071161:Forkhead Box Protein O1; D051858:Forkhead Transcription Factors / Q000235:genetics* / Q000378:metabolism; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology / Q000627:therapeutic use; D063151:Polycomb Repressive Complex 2; D017346:Protein Serine-Threonine Kinases / Q000235:genetics* / Q000378:metabolism; D011565:Psoriasis / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D009418:S100 Proteins / Q000235:genetics / Q000378:metabolism; D012867:Skin / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D014157:Transcription Factors / Q000235:genetics* / Q000378:metabolism
D004268:DNA-Binding Proteins; C085126:FOXO1 protein, human; D000071161:Forkhead Box Protein O1; D051858:Forkhead Transcription Factors; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D009418:S100 Proteins; D014157:Transcription Factors; C498409:EZH2 protein, human; D000071221:Enhancer of Zeste Homolog 2 Protein; D063151:Polycomb Repressive Complex 2; C576917:AURKA protein, human; C576921:AURKB protein, human; D064096:Aurora Kinase A; D064107:Aurora Kinase B; D064127:Aurora Kinases; D017346:Protein Serine-Threonine Kinases; D000068800:Etanercept